Candid Therapeutics key facts
as of Oct 2026- Operator of a biotechnology research designed to create novel, easy-to-administer therapies for autoimmune diseases.
- Candid Therapeutics is valued at approximately $657.0M as of Oct 2026, set at its Series B, Aug 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $445.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($370.0M) in Aug 2024.
- Notable investors include Fidelity Management & Research Company, Qiming Venture Partners, OrbiMed, Franklin Resources, Venrock — 21 tracked in total.
- 3 institutional filers report fund marks on Candid Therapeutics across 36 filings.
- Candid Therapeutics has filed 1 Form D with the SEC, most recently Sep 2024 ($206.2M sold to 33 investors).
- Status: Privately Held (backing).
Valued at $657.0M at its Series B, Aug 2024. Nothing has traded since.
- ·The complete investor list: 21 names
- ·Watch Candid Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Candid Therapeutics
3 filers · latest Jul 20263 SEC-registered funds reported 36 fair-value marks on Candid Therapeutics between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Candid Therapeutics funding rounds
1 roundsWho backs Candid Therapeutics
21+Candid Therapeutics valuation
Candid Therapeutics was valued at $657 million at its Series B in Aug 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Candid Therapeutics's record added 8 institutional fund marks (latest period Jul 2026).
How much has Candid Therapeutics raised?
Candid Therapeutics has raised $445 million across 1 recorded round since 2024. The largest was a $370 million Series B in Aug 2024.
Candid Therapeutics has filed 1 Form D with the SEC, most recently in Sep 2024 ($206 million sold to 33 investors).
Institutional holders and vehicles
3 SEC-registered funds reported 36 fair-value marks on Candid Therapeutics between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Candid Therapeutics investors
21 investors are on record for Candid Therapeutics, including Fidelity Management & Research Company, Qiming Venture Partners, OrbiMed and Franklin Resources. By type, the record holds 6 venture capital firms, 2 private equity firms and 1 asset manager. The Series B in Aug 2024 drew 20 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Abcuro ($700 million), Kardigan ($646 million) and VeraDermics (NYS: MANE) ($596 million).
About Candid Therapeutics
Operator of a biotechnology research designed to create novel, easy-to-administer therapies for autoimmune diseases. The company offers advanced T-cell engager antibodies, precisely redirecting T-cells to selectively eliminate autoreactive B-cells, enabling patients with autoimmune diseases to experience transformative efficacy and improved therapeutic outcomes.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2024
- Employees
- 35
- Website
- candidrx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.